A case series demonstrates that rapidly infusing lower-dose ketamine for fracture reduction in children is possible, but the study should not alter practice.
As a procedural sedation agent, ketamine is given to children at a dose of 1.0 to 1.5 mg/kg and is recommended to be infused over 30 to 60 seconds. Investigators hypothesized that a more rapid infusion, over only 5 seconds, might allow lower dosing.
In a single-center pilot study, 60 healthy children aged 2 to 17 years with forearm fractures were given various doses of ketamine prior to fracture reduction. Most participants (93%) received opioid premedication. Overall, 95% of children were effectively sedated with a dose of 0.7 to 0.8 mg/kg. However, the investigators monitored the effectiveness of sedation only during the initial 5 minutes of reduction attempts. Adverse events were mild and mostly limited to vomiting.
Reviewing Author
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals
DisclosuresConsultant/Advisory BoardPortola Pharmaceuticals, Inc.
Speaker’s BureauPeerView Institute for Medical Education
Grant/Research SupportAgency for Healthcare Research and Quality; CDC; NIH–National Center for Advancing Translational Sciences; NIH–National Institute of Allergy and Infectious Diseases (NIAID); NIH–NIAID–Antibacterial Resistance Leadership Group; Merck; Pfizer; Boehringer-Ingelheim; Shire; Portola Pharmaceuticals, Inc.; Novartis; bioMérieux; Siemens; Rapid Pathogen Screening; Magnolia; Stago; Innovative Biosensors; Molecular Detection, Inc.; Dyax Corp.; Trius Pharmaceuticals